EGFR and non-small cell lung carcinoma: Studies show that mTORC2 is significantly activated in EGFR-mutant non-small cell lung cancer (NSCLC), and its functional upregulation is closely associated with tumor invasiveness, epithelial-mesenchymal transition (EMT), and TKI resistance (108).